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Mariusz Gąsior1, Andrzej Szafranek1 and Lech Poloński1Abstract
Background: Data regarding the association between red cell distribution width (RDW) values and mortality in
patients with stable coronary artery disease are scarce. We aimed to investigate the link between mortality and
RDW in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI).
Methods: We analyzed 2550 consecutive patients with stable coronary artery disease who underwent PCI between
2007 and 2011 at our institution. The patients were divided into four groups according to RDW quartiles. The
association between the RDW values and the outcomes was assessed using Cox proportional regression analysis
after adjusting for clinical, echocardiographic, hemodynamic and laboratory data in the whole population and in
subgroups stratified by gender, presence of diabetes, anemia or heart failure.
Results: In the entire population, there was a stepwise relationship between RDW intervals and comorbidities.
Patients with the highest RDW values were older and more often burdened with diabetes, heart failure and
chronic kidney disease. There was an almost 4-fold increase in mortality during an average of 2.5 years of follow-up
between the group of patients with RDW values lower than 13.1% (25th percentile) and the group with RDW values
higher than 14.1% (75th percentile), (4.3% vs. 17.1%, p < 0.0001). After adjusting for the covariates, RDW remained
significantly associated with mortality in the whole cohort (HR-1.23 [95% CI (1.13-1.35), p < 0.0001]) and in the
subgroups stratified by gender, age (over and under 75 years), presence of anemia, diabetes, heart failure and
chronic kidney disease.
Conclusion: Higher RDW values correspond to higher comorbidity burdens and higher mortality. RDW is an
independent predictor of mortality in patients with stable coronary artery disease.
Keywords: Red cell distribution width, Stable coronary artery disease, PrognosisBackground
Red cell distribution width (RDW) is a numerical meas-
ure of erythrocyte variability and heterogeneity (i.e., ani-
socytosis). RDW is elevated in patients with anemia or
thalassemia and after a blood transfusion or in the pres-
ence of iron deficiency [1]. The upper and lower limits
of the RDW values were set at the 5th (11.0%) and 95th* Correspondence: tadeusz.osadnik@sccs.pl
1IIIrd Chair and Department of Cardiology, Silesian Centre for Heart Diseases,
Medical University of Silesia in Katowice, Medical Faculty in Zabrze, Ul. Marii
Skłodowskiej Curie 9, 41-800, Zabrze, Poland
Full list of author information is available at the end of the article
© 2013 Osadnik et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.(14.0%) percentiles in a population from a National
Health and Nutrition Examination Survey III study. In
recent years there have been studies referring to patients
with heart failure [2], with acute coronary syndromes
[3] and unselected patients undergoing percutaneous
coronary intervention (PCI) [4,5] and various non-
cardiological conditions [6-8]. To the best of our know-
ledge, there was only one smaller study referring to
consecutive patients with stable coronary artery disease
undergoing elective stent implantation with eight regis-
tered deaths in the 12 months follow-up [9], and two re-
ferring to subsets of patients with stable coronary arteryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tween mortality and RDW in the wide spectrum of pa-
tients with stable coronary artery disease undergoing
PCI with stent implantation over long term follow-up.
Methods
Study group
Data from consecutive patients with stable coronary
artery disease undergoing stent implantation between
2007 and 2011 at our institution (the Silesian Center for
Heart Diseases) were analyzed. To identify patients with
stable coronary artery disease, we screened all patients
with the diagnosis codes of I25.0 and I25.2, as well as
patients with other diagnoses who met the following cri-
teria: i) elective hospital admission and ii) stent implant-
ation. Patients undergoing concomitant transcatheter
aortic valve implantation procedure, patients undergoing
hybrid revascularization, and patients after orthotropic
heart transplant were not considered in the first place.
We have identified 2774 patients with stable coronary
artery disease. Patients who died during hospitalization
(n = 4), patients on dialysis (n = 11), those with advanced
valve disease (n = 203), a history of cancer (n = 26) or
other diseases potentially limiting survival (n = 18) were
excluded from the analysis. Final cohort consisted of
2550 patients.
Data source
Starting in 2006, it has been compulsory for every at-
tending physician at our Institution to fill out a complex
report form for all admitted patients. This report form
includes clinical data, past medical history and per-
formed procedures. The form includes detailed data on
a patient’s medical history and clinical characteristics at
admission, and it resembles the cardiac report form used
in clinical studies. Before patient documentation is given
to the hospital information archive, the course of
hospitalization is entered, and the report form is
checked for completeness. Despite these strict measures,
11 (0.4%) patients were found to have missing data
regarding information on the family history (FH) of
premature coronary heart disease (CHD), Canadian Car-
diovascular Society class, heart rate or systolic blood
pressure (SBP) at admission. Data on ejection fraction
were available for 2322 (91.1%) patients. Hemodynamic
data were available for all patients and were taken from
angiography descriptions. Creatinine, sodium levels and
complete blood counts were available for all patients.
The complete blood counts were performed using the
Sysmex XS1000i and XE2100 (Sysmex Corporation,
Kobe, Japan). Red cell distribution width (RDW) is cal-
culated using the following formula: RDW= (standard
deviation of red blood cell corpuscular volume)/(mean
corpuscular volume (MCV)) × 100 [%]. The creation ofthe database of patients with stable coronary artery
disease used in this study was supported by the National
Science Center – Dec-2011/01/D/NZ5/04387. Study was
approved by ethics committee at district chamber of
physicians.
Statistical analysis
The continuous variables are presented as the means
and standard deviations. The categorical variables are
presented as percentages. Patients were divided into sub-
groups according to RDW quartiles. Group I (n = 607)
comprised patients with an RDW< 13.1% (1st quartile),
group II (n = 574) comprised patients with an RDW
value of ≥13.1% and < 13.6% (2nd quartile), group III
(n = 663) comprised patients with RDW values of ≥
13.6% and <14.1% (3rd quartile) and group IV (n = 706)
comprised patients with RDW values ≥ 14.1% (4th quar-
tile). To test for differences across all groups, the chi
square and Kruskall-Wallis tests were used.
Survival and regression analysis
The associations between the RDW quartiles and mor-
tality were analyzed using the Kaplan-Meier method
with log-rank testing. To assess the impact of the RDW
on prognosis, a multivariate Cox regression analysis was
performed. RDW was imputed as a continuous variable.
To minimize the impact of missing data on the Cox re-
gression analysis, the multiple imputation method was
used to impute missing data for the variables that were
to be included in the Cox regression procedures. The
model was adjusted for age, sex, heart failure, atrial fib-
rillation, hypertension, previous myocardial infarction
(MI), previous PCI, previous coronary artery bypass graft
surgery (CABG), previous sudden cardiac death (SCD),
peripheral vascular disease (PVD), previous stroke,
diabetes, lipid abnormalities, obesity, chronic obstructive
pulmonary disease (COPD), chronic kidney disease
(CKD), smoking, New York Heart Association (NYHA)
and CCS class, heart rate, blood pressure, ejection frac-
tion, number and type(s) of stent implanted, number of
PCI vessels, hemoglobin, MCV. Additionally stratified
analyses according to gender, age (over or under 75
years) diabetes, CKD, anemia, and heart failure status
were performed. Difference in Cox-model including
aforementioned variables was compared with Cox model
including additionally RDW using likelihood ratio test.
Discriminative ability of those two models was assessed
using Harrell’s C-statistics [12]. We have also compared
those models by means of Net Reclassification Improve-
ment (NRI) and Integrated Discrimination Improvement
(IDI). NRI estimates if the addition of new variable
correctly increases or decreases the predicted risk for
events and non-events [13-16]. We have calculated
NRI using predicted probabilities estimated by Cox
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scribes differences in integrated sensitivity and inte-
grated one minus specificity between models [13].
Follow-up data
Information on survival was based on the National
Health Fund (NFZ) insurance status, which can be
electronically verified. Because the NFZ insurance
policy is obligatory for all Polish citizens, patients
who were insured were marked as alive. We madeTable 1 Baseline clinical characteristics by quartiles of RDW
Group I Group II
N = 607 N = 574
<13.1% 13.1 ≥ and <13.6
Age (yrs) 62.3 ± 9.5 63.3 ± 9.4
Men (%) 436 (71.8) 408 (71.1)
Heart failure 67 (11.0) 69 (12.0)
Atrial fibrillation 39 (6.4%) 50 (8.7%)
Hypertension 428 (70.5) 431 (75.1)
Previous MI 343 (56.5%) 320 (55.7%)
Previous CABG 69 (11.4) 83 (14.5)
Previous PCI 307 (50.6) 274 (47.7)
Previous SCD 10 (1.6%) 20 (3.5)
PVD 24 (4.0) 34 (5.9)
Prev. Stroke/TIA 19 (3.1) 27 (4.7)
CKD GFR < 60 ml/h/1.73 m2 40 (6.6) 59 (10.3)
Diabetes 210 (34.6) 215 (37.5)
Insulin 61 (10.0) 86 (15.0)
Lipid abnormalities 363 (59.8) 357 (62.2)
Obesity 203 (33.4) 192 (33.4)
COPD 32 (5.3) 35 (6.1)
Current smoker 59 (9.7) 65 (11.3)
Previous smoker 202 (33.3%) 196 (34.1)
FH of premature CHD 65 (10.7) 48 (8.4)
NYHA class III/IV 28 (4.6%) 40 (7.0%)
Disabling angina (CCS III/IV) 97 (16.0) 92 (16.0)
HR (1/min) 69.3 ± 10.9 70.2 ± 11.4
SBP (mmHg) 133± 19.7 133.0 ± 19.7
DBP (mmHg) 79.3 ± 10.8 78.9 ± 11.3
Sinus rhythm - 588 (96.9) 547 (95.3)
Ejection fraction (%) 46.7 ± 9.7 47.8 ± 9.48
BMS 253 (41.7%) 284 (49.5%)
MVD 68 (11.2) 92 (16.0)
No. of PCI vessels 1.2 ± 0.5 1.2 ± 0.5
No. of stents 1.4 ± 0.7 1.4 ± 0.7
MI – myocardial infarction, CABG – coronary artery bypass graft, PCI – percutaneou
disease, FH – family history, CKD – chronic kidney disease, CHD – coronary heart di
Cardiovascular Society class, HR – heart rate, SBP – systolic blood pressure, DBP – dan attempt to contact the relatives of uninsured pa-
tients and/or the relevant local registry office to ob-
tain the exact date of death. Follow-up data were
available for 2535 (99.4%) of patients. The mean
follow-up period was 915.4 ± 525.3 days. During the
observation period, there were 233 reported deaths.
All reported p-values are two-sided. The analyses
were performed using Number Crunching Statistical
Systems 8.0 (NCSS, Kaysville, UT, USA) and in R
software [17].Group III Group IV P value
N = 663 N = 706
% 13.6% ≥ and <14.1% ≥14.1
64.4 ± 9.3 65.6 ± 9.1 <0.0001
461 (69.5) 494 (70.0) 0.8
77 (11.7) 146 (20.7) <0.0001
75 (11.3%) 123 (17.4) <0.0001
477 (71.9) 491 (69.5) 0.15
373 (56.3%) 437 (61.9%) 0.07
89 (13.4) 99 (14.0) 0.38
306 (46.2) 367 (52.0) 0.08
21 (3.2) 26 (3.7) 0.14
37 (5.6) 47 (6.7) 0.19
39 (5.9) 60 (8.5) 0.0003
91 (13.7) 137 (19.4) <0.0001
238 (35.9) 280 (39.7) 0.26
85 (12.8) 127 (18.0) 0.0004
387 (58.4) 353 (50.0) <0.0001
234 (35.3) 252 (35.7) 0.75
45 (6.8) 79 (11.2) 0.0001
73 (11.0) 85 (12.0) 0.68
226 (34.1) 259 (36.7) 0.67
70 (10.6) 47 (6.7) 0.11
33 (5.0%) 86 (12.2%) <0.0001
115 (17.3) 115 (16.3) 0.9
71.9 ± 11.8 73.0 ± 12.9 <0.0001
132.3 ± 18.5 132 ± 20.6 0.65
78.8 ± 10.6 78.4 ± 12.0 0.20
620 (93.5) 632 (89.5) <0.0001
46.4 ± 10.0 43.8 ± 11.4 <0.0001
387 (58.4%) 435 (61.6%) <0.0001
106 (16.0) 113 (16.0) 0.04
1.2 ± 0.5 1.3 ± 05 0.82
1.3 ± 0.6 1.4 ± 0.7 0.41
s coronary intervention, SCD – sudden cardiac death, PVD – peripheral vascular
sease, NYHA – New York Heart Association class, CCS – Canadian
iastolic blood pressure, BMS – bare metal stent, MVD – multivessel disease.
Table 2 Laboratory findings by quartiles of RDW
Group I Group II Group III Group IV P value
N = 607 N = 574 N = 663 N = 706
<13.1% 13.1 ≥ and <13.6% 13.6% ≥ and <14.1% ≥14.1 %
RBC (mln/mm3) 4.5 ± 0.4 4.5 ± 0.5 4.5 ± 0.5 4.5 ± 0.5 0.02
HGB (mmol/l) 8.7 ± 0.8 8.6 ± 0.9 8.6 ± 0.8 8.3 ± 1.0 <0.0001
HCT (%) 40.4 ± 3.4 40.6 ± 4.3 40.8 ± 3.8 39.8 ± 4.4 <0.0001
MCV (mm3) 90.6 ± 3.9 89.0 ± 3.8 90.5 ± 4.3 89.9 ± 5.6 0.01
RDW (%) 12.6 ± 0.4 13.3 ± 0.1 13.8 ± 0.2 15.0 ± 1.2 <0.0001
WBC (tys/mm3) 7.1 ± 1.9 7.3 ± 2.0 7.4 ± 2.6 7.4 ± 2.2 0.17
PLT (tys/mm3) 211.3 ± 51.3 210.0 ± 59.4 207.4 ± 60.6 213.3 ± 73.7 0.19
Creatinine (μmol/l) 79.8 ± 32.6 80,3 ± 22.8 83,2 ± 24.7 89,8 ± 48.1 <0.0001
GFR (ml/min/1.73 m2) 90.0 ± 21.9 89.4 ± 25.5 85.5 ± 24.2 82,4 ± 26.5 <0.0001
Sodium (mmol/l) 138.5 ± 2.6 138.3 ± 2.8 138.7 ± 2.64 138.5 ± 2.8 0.09
Glucose (mmol/l) 6.2 ± 2.0 6.1 ± 2.0 6.0 ± 1.6 5.9 ± 1.7 0.18
Cholesterol (mmol/l) 4.3 ± 1.1 4.5 ± 1.2 4.4 ± 1.1 4.5 ± 1.3 0.08
RBC – red blood cells, HGB – hemoglobin, HCT – hematocrit, MCV – mean corpuscular volume, RDW – red cell distribution width, WBC – white blood cells,
PLT – platelets, GFR – glomerular filtration rate.
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Baseline characteristics of the entire population
The baseline clinical characteristics for the entire popula-
tion are shown in Table 1. In general, patients with the
highest RDW values were older and more often burdened
with diabetes, heart failure, CKD, COPD and PVD. More-
over, patients with higher RDW values had higher heart
rates and lower ejection fractions. Not surprisingly, the
lowest hemoglobin values were observed in patients with
the highest RDW values (Table 2). The prescribed treat-
ments at discharge reflected differences in comorbidities:
more nitrates and diuretics were prescribed in patients
with the highest RDW values (Table 3).
Survival analysis and predictors of outcome
During the observation period, there were 233 reported
deaths. Mortality in quartiles 1 to 3 was significantly lowerTable 3 Prescribed treatment at discharge by quartiles of RD
Group I Group II
N = 607 N = 574
<13.1% 13.1 ≥ and <13.6
Aspirin 601 (99.0) 569 (99.1)
Clopidogrel/Thienopiridines 607 (100) 572 (99.7)
ACE-I/ARB 585 (96.4) 539 (93.9)
Beta-blockers 581 (95.7) 555 (96.7)
Calcium channel blockers 106 (17.5) 82 (14.3)
Diuretics 203 (33.4) 194 (33.8)
Nitrates 121 (19.9) 166 (28.9)
VKA 23 (3.8) 32 (5.6)
ACE-I – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blockas compared with quartile 4 (quartile 1 – 26 (4.3%); quartile
2 – 39 (6.8%); quartile 3–48 (7.3%); quartile 4–120 (17.1%),
p < 0.0001, respectively) Figure 1. RDW was highly signifi-
cantly associated with mortality in the entire cohort and in
a subset of patients stratified by age, gender, anemia status,
CKD, diabetes and heart failure (Table 4). Adding RDW to
model based on clinical variables, ejection fraction
hemodynamic data creatinine, and MCV resulted signifi-
cantly improved the model (p < 0.001) although Harrell’s-C
statistic increased only slightly from 0.76 (95% CI,
0.69÷0.82) to 0.77 (95% CI, 0.70÷0.83). Adding RDW to
model based on clinical, hemodynamic and laboratory pa-
rameters (including MCV) however did not change IDI sig-
nificantly (IDI − 0.019 95% CI: − 0.005 ÷ 0.051, p =0.120).
There was also non-significant change in the risk of death
predicted by the models with and without RDW (NRI −
0.251 95% CI: − 0.163 ÷ 0.512 p = 0.213).W
Group III Group IV P value
N = 663 N = 706
% 13.6% ≥ and <14.1% ≥14.1%
658 (99.2) 693 (98.2) 0.21
658 (99.2) 699 (99.0) 0.25
622 (93.8) 641 (90.8) 0.0006
630 (95.0) 671 (95.0) 0.44
100 (15.1) 112 (15.9) 0.47
229 (34.5) 315 (44.6) <0.0001
223 (33.6) 233 (33.0) <0.0001
47 (7.1) 83 (11.8) <0.0001
ers, VKA – vitamin K antagonists.
Figure 1 Kaplan Meier survival curves by quartiles of RDW.
Table 4 Adjusted* hazard ratios of RDW [per 1%
increase] in whole population and in subgroups
Hazard ratio 95% CI P value
Whole group 1.23 1.13-1.35 <0.0001
Females 1.31 1.06-1.62 0.01
Males 1.22 1.1-1.34 0.0001
≥75 years 1.36 1.05-1.78 0.02
<75 years 1.21 1.09-1.33 0.0003
Anemia 1.17 1.02-1.34 0.02
Without anemia 1.37 1.19-1.58 <0.0001
With CKD 1.49 1.32-1.82 0.0001
Without CKD 1.16 1.04-1.29 0.009
Diabetes 1.23 1.08-1.4 0.002
Without diabetes 1.27 1.12-1.46 0.0003
Heart failure 1.20 1.04-1.39 0.01
Without heart failure 1.39 1.07-1.8 0.01
Adjusted for age, sex, heart failure, atrial fibrillation, hypertension, previous MI,
previous PCI, previous CABG, previous SCD, PVD, previous stroke, diabetes,
lipid abnormalities, obesity, COPD, CKDsmoking, NYHA and CCS class, heart
rate, blood pressure, ejection fraction, number and type(s) of stent implanted,
number of PCI vessels, hemoglobin, MCV.
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There are two main findings of this study. First, with in-
creasing values of RDW, there is an increase in the rate
of patients with serious comorbidities such as COPD,
PVD, diabetes treated with insulin, atrial fibrillation and
heart failure in the entire population. Second, the RDW
was associated with mortality, even after adjusting for
clinical echocardiographic and hemodynamic variables
in the whole population and in various subgroups. Mor-
tality in the patients with the highest RDW values was
almost 4-fold higher than in patients with the lowest
RDW values. Similar results were obtained by Fatemi O.
and Tonelli M. et al., who observed a graded relationship
between RDW quartiles and mortality in patients with
various forms of coronary artery disease [4,11], and by
Patel V.K., who reported an increase in mortality across
RDW quintiles in the general population [18]. In a re-
cent study, Ren H. et al. reported that similar trends of
mortality and RDW may be present in patients with
stable coronary artery disease because they registered 8
deaths (2.27%) vs. 2 deaths (0.51%) [9] in patients with
RDW values in the highest and lowest RDW quartiles,
respectively. Our analysis of a larger population with a
longer follow-up period and 233 registered events con-
firms those findings.
RDW as a marker of disease burden
An increased percentage of patients with serious comor-
bidities compared to patients with lower RDW values
suggests that RDW is a universal marker of disease bur-
den. Data from analyses referring to the wide spectrumof diseases seem to confirm that finding [3,18-28].
Associations between higher RDW levels and CKD are
quite easy to explain because anemia, which is fre-
quently found in patients with impaired renal function
[29,30], is associated with increased RDW values. More-
over, RDW values are often used for anemia classifica-
tion [31]. An explanation similar to that for CKD may
hold for heart failure because Jankowska E et al. showed
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heart failure [32]. In our study, the frequency of heart
failure and the percentage of patients with advanced
heart failure symptoms were higher in patients with
RDW values within the 4th quartile. The association of
RDW with other comorbidities such as COPD, diabetes
and peripheral vascular disease may be more difficult to
elucidate. Possible explanations come from publications
describing the increased inflammatory status and in-
creased oxidative stress in those conditions [33-38].
Therefore, in more advanced stages of atherosclerosis,
COPD and diabetes, the detrimental effects of oxidative
stress on erythrocyte membrane fluidity affects the life-
span of red blood cells, which in turn leads to higher
RDW values [39]. However, Fornal M et al. and Lippi G
et al. [40,41] reported the existence of a potential link
between inflammatory biomarkers and RDW values that
may also be of importance, because the inflammation
may impair iron metabolism and inhibit both the pro-
duction of and the response to erythropoietin [18,42].
Veranna V. et al. reported that RDW values of 12.6%
and increased CRP levels above 3 mg/dl are associated
with a higher risk of mortality in a cohort free of coron-
ary heart disease [43]. Another interesting observation is
the lower frequency of multivessel coronary artery dis-
ease (MVD) in patients with RDW values in the 1st
quartile compared to the other quartiles, which is in
concordance with results of Isik T. et al. and MA F-L
[44,45]. Those findings may indirectly confirm the asso-
ciation of increasing values of RDW with extensiveness
and possibly the duration of the atherosclerotic process
and the role of RDW as a marker of the disease process.
Red blood cell heterogeneity as a potential causative
factor
The association between RDW values and comorbidities
does not entirely explain the increased mortality in
patients with the highest RDW values because RDW
remained highly significantly associated with mortality
after adjusting for clinical echocardiographic, hemody-
namic and laboratory parameters in the entire cohort
and in subgroups, although in our study it did not im-
prove risk prediction as estimated by NRI and IDI mea-
sures. There have been however studies showing that
RDW improves prediction of bleeding after acute coron-
ary syndromes [46] and mortality in kidney transplant
recipients [47].
Currently, it is not clear why higher RDW levels are so
strongly associated with worse long term prognoses in
various diseases. Luneva O.G. et al. provided insight into
the pathophysiology of the relationship between mortal-
ity and RDW values by finding a significant correlation
between RDW values and the cholesterol content of
erythrocyte membranes, which also determines erythro-cyte membrane fluidity [39]. It has also been reported
that greater variation in RDW is associated with im-
paired blood flow through the microvascular system,
which may cause tissue hypoxia, even in patients with-
out anemia [48].
Strengths and limitations
A limitation of this study is the retrospective design.
Nonetheless, the potential disadvantages of this retro-
spective analysis are diminished by the fact that the pa-
tient data are inputted into an electronic database from
report forms filled out by the attending physician upon
the patient’s admission to our center. Other limitations
include a lack of iron status and other biomarkers such
as high sensitivity troponins.
Strengths of this study include large cohort, detailed
data on clinical, echocardiographic hemodynamic and
laboratory parameters, and long follow-up period with
very little patients lost to follow-up.
Conclusions
RDW is an independent predictor of mortality in pa-
tients with stable coronary artery disease undergoing
stent implantation. Higher RDW values correspond with
a higher comorbidity burden and higher mortality in a
stepwise fashion, even within the RDW reference range.
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